04
Dec

Months removed from its last late-stage failure, animal health biotech Kindred Biosciences is pulling the plug on another pivotal trial, sending its shares into tailspin just a year after its IPO.

…read more

Source: Kindred dumps its dog eczema drug in another pipeline setback

    

0 No comments